Carbapenem Market Key Players Analysis 2031
The Carbapenem Market is expected to register a CAGR of 4.8% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The Carbapenem market report is segmented by product type into the following subsegments: Meropenem, Doripenem, Imipenem, and Tebipenem. It further presents an analysis based on indications, including Bacterial Meningitis, Acute Pelvic Infections, and Respiratory Tract Infections. The distribution channels are also examined, such as Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Carbapenem Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Carbapenem Market Segmentation
Type- Meropenem
- Doripenem
- Imipenem Tebipenem
- Bacterial Meningitis
- Acute Pelvic Infections
- Respiratory Tract Infections
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Strategic Insights
Carbapenem Market Growth Drivers- Antibiotic-resistant infections: Particularly multidrug-resistant bacterium causing infections, as a major driver. Carbapenems represent a variant of the last resort for these infections and are therefore very crucial in patient management.
- Growing healthcare expenditure: Enhancements in healthcare infrastructure and rising availability of quality healthcare services will enhance carbapenem consumption. Older patients are susceptible to infections, while elderly patients would require effective antibiotics like carbapenems. The current and future R&D investments by the pharmaceutical industry in the development of new formulations and combination therapies with innovative combinations of carbapenems will positively drive this market. These improvements strive to enhance the efficacy, minimize adverse effects, and expand the therapeutic scope of carbapenems.
- Growing concerns over antibiotic resistance: Healthcare providers and policymakers are focusing on proper antimicrobial prescribing for the reduction of drug-resistant bacteria. The future outlook of the carbapenem market looks bright with hopeful promises and is mainly driven by several key trends.
- Demand for effective antibiotics such as carbapenems: Since bacteria continue evolving and growing resistant to the options of treatments, carbapenems will remain one of the most critical tools to fight these infections. The market will be further driven by the rising incidence of chronic diseases and the worsening immunological system among the elderly population. Research and development to enhance and improve carbapenem formulations, as well as new delivery systems, are being pursued continuously. This enhancement focuses on the improved efficacy, safety, and accessibility of carbapenem therapy.
- Bright future of the carbapenem market: The growing need for infection prevention practices in hospitals will fuel the carbapenem market as they are applied to inhibit and treat hospital-acquired infections. However, challenges such as increased regulatory pressure on pharmaceutical firms and increasing carbapenem-resistant bacteria strains may negatively impact the growth of the market. To achieve the above aims, pharmaceutical firms are propagating novel approaches that include combination therapy and targeted drug delivery systems. Hence, the future of the carbapenem market seems bright, especially to fight with the increasing menace of antibiotic-resistant bacteria and also to increase the effectiveness of patient treatment.
- Pipeline of Novel Carbapenem Formulations:
Continuous R&D in improving carbapenem efficacy and reducing resistance through combination therapies is fueling market growth.
- Rising number of antibiotic-resistant infections: Numerous significant opportunities lie in the development and innovation areas for this market. The most important area would be the constantly on-rising number of antibiotic-resistant infections, especially those caused by multidrug-resistant bacteria. Therefore, the market would be in a position to realize growth opportunities in the application of carbapenems as last-line therapy during the forecasted period.
- Innovative drug formulations and combination therapies: Differing products, like drug companies, could seek to enhance the delivery mechanism of the drug while improving efficacy and reducing side effects. In addition, burgeoning healthcare expenditure and improving healthcare infrastructure in emerging markets offer significant opportunities for the carbapenem market.
- Emphasis on infection prevention: Greater emphasis on prevention as well as infection and control in healthcare facilities offers potential for the creation and dissemination of preventive carbapenem therapies. Such infection-preventing therapies reduce the cost and improve the outcome of patient care. The crisis with antibiotic resistance has to be addressed by sustainable use of carbapenems in an optimum manner to fully exploit their therapeutic potential.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Carbapenem Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Carbapenem Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Carbapenem Market is expected to grow at a CAGR of 4.8% between 2023-2031
The carbapenem market is primarily driven by the escalating prevalence of antibiotic-resistant infections. These infections, particularly those caused by multidrug-resistant bacteria, pose a significant threat to global health. Carbapenems, often considered a last-line defense against these infections, are essential for treating severe bacterial infections. Additionally, the rising healthcare expenditure globally, coupled with the growing geriatric population, is fueling the demand for effective antibiotics like carbapenems. Furthermore, product advancements in drug discovery and development are also pushing the market ahead, as this will ensure innovations in formulations and combination therapies.
Trends driving the future of the carbapenem market include persistent increases in antibiotic-resistant infections, which will drive demand for appropriate antibiotics such as carbapenems. Further developments in pharmaceutical drug discovery and development, such as the creation of innovative formulations and combination therapies, will enhance the efficacy and safety of carbapenems. Infection prevention and control measures have become an area of higher concern in the healthcare sector, so growth in the market will be encouraged through these factors. However, market growth may be affected by potential obstacles such as resistance to carbapenem-based bacteria and strict regulation.
The leading players of the market are: Spero Therapeutics, Inc., Savior Lifetec Corporation, Meiji Seika Pharma Co., Ltd., Merck & Co., Inc., Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.), Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co., Ltd., Iterum Therapeutics plc, ACS Dobfar S.p.A.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Carbapenem - By Type
1.3.2 Carbapenem - By Indication
1.3.3 Carbapenem - By Distribution Channel
1.3.4 Carbapenem - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CARBAPENEM LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CARBAPENEM - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CARBAPENEM - GLOBAL MARKET ANALYSIS
6.1. CARBAPENEM - GLOBAL MARKET OVERVIEW
6.2. CARBAPENEM - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CARBAPENEM - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. MEROPENEM
7.3.1. Overview
7.3.2. Meropenem Market Forecast and Analysis
7.4. DORIPENEM
7.4.1. Overview
7.4.2. Doripenem Market Forecast and Analysis
7.5. IMIPENEM TEBIPENEM
7.5.1. Overview
7.5.2. Imipenem Tebipenem Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. CARBAPENEM - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. BACTERIAL MENINGITIS
8.3.1. Overview
8.3.2. Bacterial Meningitis Market Forecast and Analysis
8.4. ACUTE PELVIC INFECTIONS
8.4.1. Overview
8.4.2. Acute Pelvic Infections Market Forecast and Analysis
8.5. RESPIRATORY TRACT INFECTIONS
8.5.1. Overview
8.5.2. Respiratory Tract Infections Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. CARBAPENEM - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. RETAIL PHARMACIES
9.3.1. Overview
9.3.2. Retail Pharmacies Market Forecast and Analysis
9.4. ONLINE PHARMACIES
9.4.1. Overview
9.4.2. Online Pharmacies Market Forecast and Analysis
9.5. HOSPITAL PHARMACIES
9.5.1. Overview
9.5.2. Hospital Pharmacies Market Forecast and Analysis
10. CARBAPENEM REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Carbapenem Overview
10.1.2 North America Carbapenem Forecasts and Analysis
10.1.3 North America Carbapenem Forecasts and Analysis - By Type
10.1.4 North America Carbapenem Forecasts and Analysis - By Indication
10.1.5 North America Carbapenem Forecasts and Analysis - By Distribution Channel
10.1.6 North America Carbapenem Forecasts and Analysis - By Countries
10.1.6.1 United States Carbapenem
10.1.6.1.1 United States Carbapenem by Type
10.1.6.1.2 United States Carbapenem by Indication
10.1.6.1.3 United States Carbapenem by Distribution Channel
10.1.6.2 Canada Carbapenem
10.1.6.2.1 Canada Carbapenem by Type
10.1.6.2.2 Canada Carbapenem by Indication
10.1.6.2.3 Canada Carbapenem by Distribution Channel
10.1.6.3 Mexico Carbapenem
10.1.6.3.1 Mexico Carbapenem by Type
10.1.6.3.2 Mexico Carbapenem by Indication
10.1.6.3.3 Mexico Carbapenem by Distribution Channel
10.2. EUROPE
10.2.1 Europe Carbapenem Overview
10.2.2 Europe Carbapenem Forecasts and Analysis
10.2.3 Europe Carbapenem Forecasts and Analysis - By Type
10.2.4 Europe Carbapenem Forecasts and Analysis - By Indication
10.2.5 Europe Carbapenem Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Carbapenem Forecasts and Analysis - By Countries
10.2.6.1 Germany Carbapenem
10.2.6.1.1 Germany Carbapenem by Type
10.2.6.1.2 Germany Carbapenem by Indication
10.2.6.1.3 Germany Carbapenem by Distribution Channel
10.2.6.2 France Carbapenem
10.2.6.2.1 France Carbapenem by Type
10.2.6.2.2 France Carbapenem by Indication
10.2.6.2.3 France Carbapenem by Distribution Channel
10.2.6.3 Italy Carbapenem
10.2.6.3.1 Italy Carbapenem by Type
10.2.6.3.2 Italy Carbapenem by Indication
10.2.6.3.3 Italy Carbapenem by Distribution Channel
10.2.6.4 Spain Carbapenem
10.2.6.4.1 Spain Carbapenem by Type
10.2.6.4.2 Spain Carbapenem by Indication
10.2.6.4.3 Spain Carbapenem by Distribution Channel
10.2.6.5 United Kingdom Carbapenem
10.2.6.5.1 United Kingdom Carbapenem by Type
10.2.6.5.2 United Kingdom Carbapenem by Indication
10.2.6.5.3 United Kingdom Carbapenem by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Carbapenem Overview
10.3.2 Asia-Pacific Carbapenem Forecasts and Analysis
10.3.3 Asia-Pacific Carbapenem Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Carbapenem Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Carbapenem Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Carbapenem Forecasts and Analysis - By Countries
10.3.6.1 Australia Carbapenem
10.3.6.1.1 Australia Carbapenem by Type
10.3.6.1.2 Australia Carbapenem by Indication
10.3.6.1.3 Australia Carbapenem by Distribution Channel
10.3.6.2 China Carbapenem
10.3.6.2.1 China Carbapenem by Type
10.3.6.2.2 China Carbapenem by Indication
10.3.6.2.3 China Carbapenem by Distribution Channel
10.3.6.3 India Carbapenem
10.3.6.3.1 India Carbapenem by Type
10.3.6.3.2 India Carbapenem by Indication
10.3.6.3.3 India Carbapenem by Distribution Channel
10.3.6.4 Japan Carbapenem
10.3.6.4.1 Japan Carbapenem by Type
10.3.6.4.2 Japan Carbapenem by Indication
10.3.6.4.3 Japan Carbapenem by Distribution Channel
10.3.6.5 South Korea Carbapenem
10.3.6.5.1 South Korea Carbapenem by Type
10.3.6.5.2 South Korea Carbapenem by Indication
10.3.6.5.3 South Korea Carbapenem by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Carbapenem Overview
10.4.2 Middle East and Africa Carbapenem Forecasts and Analysis
10.4.3 Middle East and Africa Carbapenem Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Carbapenem Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Carbapenem Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Carbapenem Forecasts and Analysis - By Countries
10.4.6.1 South Africa Carbapenem
10.4.6.1.1 South Africa Carbapenem by Type
10.4.6.1.2 South Africa Carbapenem by Indication
10.4.6.1.3 South Africa Carbapenem by Distribution Channel
10.4.6.2 Saudi Arabia Carbapenem
10.4.6.2.1 Saudi Arabia Carbapenem by Type
10.4.6.2.2 Saudi Arabia Carbapenem by Indication
10.4.6.2.3 Saudi Arabia Carbapenem by Distribution Channel
10.4.6.3 U.A.E Carbapenem
10.4.6.3.1 U.A.E Carbapenem by Type
10.4.6.3.2 U.A.E Carbapenem by Indication
10.4.6.3.3 U.A.E Carbapenem by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Carbapenem Overview
10.5.2 South and Central America Carbapenem Forecasts and Analysis
10.5.3 South and Central America Carbapenem Forecasts and Analysis - By Type
10.5.4 South and Central America Carbapenem Forecasts and Analysis - By Indication
10.5.5 South and Central America Carbapenem Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Carbapenem Forecasts and Analysis - By Countries
10.5.6.1 Brazil Carbapenem
10.5.6.1.1 Brazil Carbapenem by Type
10.5.6.1.2 Brazil Carbapenem by Indication
10.5.6.1.3 Brazil Carbapenem by Distribution Channel
10.5.6.2 Argentina Carbapenem
10.5.6.2.1 Argentina Carbapenem by Type
10.5.6.2.2 Argentina Carbapenem by Indication
10.5.6.2.3 Argentina Carbapenem by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CARBAPENEM, KEY COMPANY PROFILES
12.1. SPERO THERAPEUTICS, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. SAVIOR LIFETEC CORPORATION
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MEIJI SEIKA PHARMA CO., LTD.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. MERCK AND CO., INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAND PHARMA LTD. (FOSUN PHARMACEUTICAL CO., LTD.)
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. AUROBINDO PHARMA LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. DAEWOONG PHARMACEUTICAL CO., LTD.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ITERUM THERAPEUTICS PLC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ACS DOBFAR S.P.A.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Spero Therapeutics, Inc.
2. Savior Lifetec Corporation
3. Meiji Seika Pharma Co., Ltd.
4. Merck & Co., Inc.
5. Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.)
6. Aurobindo Pharma Ltd.
7. Daewoong Pharmaceutical Co., Ltd.
8. Iterum Therapeutics plc
9. ACS Dobfar S.p.A.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For